



Sheet 1 of 1

**COPY****INFORMATION DISCLOSURE  
CITATION**

620-162

SERIAL NO.  
09/937,714

APPLICANT

SPRINGER et al.

(Use several sheets if necessary)

FILING DATE

October 1, 2001

GROUP

-2101-1625

**FOREIGN PATENT DOCUMENTS**

							TRANSLATION	
							YES	NO
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS				
WO 88/07378	10/1988	WO	✓	—				
WO 90/02729	03/1990	WO	✓	—				
WO 91/02805	03/1991	WO	✓	—				
WO 91/03460	03/1991	WO	✓	—				
WO 92/14829	09/1992	WO	✓	—				
WO 93/10814	06/1993	WO	✓	—				
WO 94/02450	02/1994	WO	✓	—				
WO 94/21792	09/1994	WO	✓	—				
WO 95/07994	03/1995	WO	✓	—				
WO 95/14091	05/1995	WO	✓	—				
WO 96/03151	02/1996	WO	✓	—				
WO 96/03515	02/1996	WO	✓	—				
WO 96/22277	07/1996	WO	✓	—				
WO 97/26918	07/1997	WO	✓	—				
EP A 415 731	03/1991	EP	✓	—				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

✓	Bagshawe et al., "Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites" <u>Antibody, Immunoconjugates, and Radiopharmaceuticals</u> , 1991, Vol. 4, pp. 915-922.
	Cornell and Charm, "Purification of Carboxypeptidase G-1 by Immunoabsorption" <u>Biotech. and Bioeng.</u> , 1976, Vol XVIII, 1171-1173.
	Culver et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors" <u>Science</u> , 1992, Vol. 256, pp. 1550-1552.
	Englehardt et al., "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses" <u>Nature Genetics</u> , 1993, Vol. 4, pp. 27-34.
	Huber et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy" <u>Proc. Natl. Acad. Sci. USA</u> , 1991, Vol. 88, pp. 8039-8043.
	Levy and Goldman, "The Enzymatic Hydrolysis of Methotrexate and Folic Acid" <u>J. Biol. Chem.</u> , 1967, Vol. 12, 2933-2938.
	Mizushima and Nagata, "pEF-BOS, a powerful mammalian expression vector" <u>Nucl. Acids Res.</u> , 1990, Vol. 18, p. 5322.
	Niculescu-Duvaz et al., "Prodrugs for Antibody- and Gene-Directed Enzyme Prodrug Therapies (ADEPT and GDEPT)," <u>Anti-Cancer Drug Design</u> , 1999, Vol. 14, pp. 517-538.
	Springer et al., "Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)." <u>J. Med. Chem.</u> , 1995, Vol. 38, pp. 5051-5065.
	Springer et al., "Comparison of half-lives and cytotoxicity of <i>N</i> -chloroethyl-4-amino and <i>N</i> -mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT)" <u>Anti-Cancer Drug Design</u> , 1991, Vol. 6, pp. 467-479.
	Springer et al., "Novel Prodrugs Which Are Activated to Cytotoxic Alkylating Agents by Carboxypeptidase G2" <u>J. Medicinal Chem.</u> , 1990, Vol. 33, pp. 677-681.
✓	Yasuda et al., "In Vitro Antitumor Activity of Carboxypeptidase G <sub>3</sub> from <i>Pseudomonas</i> sp. M-27" <u>Bull. Mukogawa Women's Univ. Nat. Sci.</u> , 1994, Vol. 42, pp.63-66.

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.